Biotechnology
Compare Stocks
2 / 10Stock Comparison
MPLT vs ACNB
Revenue, margins, valuation, and 5-year total return — side by side.
Banks - Regional
MPLT vs ACNB — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Biotechnology | Banks - Regional |
| Market Cap | $1.33B | $544M |
| Revenue (TTM) | $0.00 | $170M |
| Net Income (TTM) | $-103M | $37M |
| Gross Margin | — | 73.7% |
| Operating Margin | — | 27.3% |
| Forward P/E | — | 9.8x |
| Total Debt | $7M | $329M |
| Cash & Equiv. | $38M | $21M |
Quick Verdict: MPLT vs ACNB
Each card shows where this stock fits in a portfolio — not just who wins on paper.
MPLT is the clearest fit if your priority is sleep-well-at-night and defensive.
- Low D/E 5.7%, current ratio 7.20x
- current ratio 7.20x
- Lower D/E ratio (5.7% vs 78.3%)
ACNB carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 28.9%, EPS growth -3.5%
- 179.5% 10Y total return vs MPLT's 62.6%
- 21.7% margin vs MPLT's 3.3%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Quality / Margins | 21.7% margin vs MPLT's 3.3% | |
| Stability / Safety | Lower D/E ratio (5.7% vs 78.3%) | |
| Dividends | 2.7% yield; 8-year raise streak; the other pay no meaningful dividend | |
| Momentum (1Y) | +62.6% vs ACNB's +22.7% | |
| Efficiency (ROA) | 1.1% ROA vs MPLT's -69.7%, ROIC 5.3% vs -153.7% |
MPLT vs ACNB — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
MPLT vs ACNB — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
Insufficient data to determine a leader in this category.
Income & Cash Flow (Last 12 Months)
ACNB and MPLT operate at a comparable scale, with $170M and $0 in trailing revenue.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $0 | $170M |
| EBITDAEarnings before interest/tax | -$108M | $53M |
| Net IncomeAfter-tax profit | -$103M | $37M |
| Free Cash FlowCash after capex | -$113M | $51M |
| Gross MarginGross profit ÷ Revenue | — | +73.7% |
| Operating MarginEBIT ÷ Revenue | — | +27.3% |
| Net MarginNet income ÷ Revenue | — | +21.7% |
| FCF MarginFCF ÷ Revenue | — | +30.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | — | +35.1% |
Valuation Metrics
Evenly matched — MPLT and ACNB each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $1.3B | $544M |
| Enterprise ValueMkt cap + debt − cash | $1.3B | $853M |
| Trailing P/EPrice ÷ TTM EPS | -15.66x | 14.61x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 9.75x |
| PEG RatioP/E ÷ EPS growth rate | — | 1.32x |
| EV / EBITDAEnterprise value multiple | — | 16.03x |
| Price / SalesMarket cap ÷ Revenue | — | 3.20x |
| Price / BookPrice ÷ Book value/share | 10.53x | 1.29x |
| Price / FCFMarket cap ÷ FCF | — | 10.36x |
Profitability & Efficiency
ACNB leads this category, winning 5 of 8 comparable metrics.
Profitability & Efficiency
ACNB delivers a 9.2% return on equity — every $100 of shareholder capital generates $9 in annual profit, vs $-2 for MPLT. MPLT carries lower financial leverage with a 0.06x debt-to-equity ratio, signaling a more conservative balance sheet compared to ACNB's 0.78x. On the Piotroski fundamental quality scale (0–9), ACNB scores 5/9 vs MPLT's 4/9, reflecting solid financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -2.1% | +9.2% |
| ROA (TTM)Return on assets | -69.7% | +1.1% |
| ROICReturn on invested capital | -153.7% | +5.3% |
| ROCEReturn on capital employed | -83.9% | +2.5% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 5 |
| Debt / EquityFinancial leverage | 0.06x | 0.78x |
| Net DebtTotal debt minus cash | -$32M | $308M |
| Cash & Equiv.Liquid assets | $38M | $21M |
| Total DebtShort + long-term debt | $7M | $329M |
| Interest CoverageEBIT ÷ Interest expense | — | 1.16x |
Total Returns (Dividends Reinvested)
ACNB leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ACNB five years ago would be worth $20,536 today (with dividends reinvested), compared to $16,263 for MPLT. Over the past 12 months, MPLT leads with a +62.6% total return vs ACNB's +22.7%. The 3-year compound annual growth rate (CAGR) favors ACNB at 24.1% vs MPLT's 17.6% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | +62.6% | +12.1% |
| 1-Year ReturnPast 12 months | +62.6% | +22.7% |
| 3-Year ReturnCumulative with dividends | +62.6% | +91.0% |
| 5-Year ReturnCumulative with dividends | +62.6% | +105.4% |
| 10-Year ReturnCumulative with dividends | +62.6% | +179.5% |
| CAGR (3Y)Annualised 3-year return | +17.6% | +24.1% |
Risk & Volatility
ACNB leads this category, winning 1 of 1 comparable metric.
Risk & Volatility
ACNB currently trades 97.5% from its 52-week high vs MPLT's 88.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | — | 0.68x |
| 52-Week HighHighest price in past year | $33.28 | $53.93 |
| 52-Week LowLowest price in past year | $16.34 | $40.15 |
| % of 52W HighCurrent price vs 52-week peak | +88.0% | +97.5% |
| RSI (14)Momentum oscillator 0–100 | 59.2 | 57.2 |
| Avg Volume (50D)Average daily shares traded | 264K | 62K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Consensus price targets imply 15.4% upside for MPLT (target: $34) vs 10.3% for ACNB (target: $58). ACNB is the only dividend payer here at 2.66% yield — a key consideration for income-focused portfolios.
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | $33.80 | $58.00 |
| # AnalystsCovering analysts | — | 2 |
| Dividend YieldAnnual dividend ÷ price | — | +2.7% |
| Dividend StreakConsecutive years of raises | — | 8 |
| Dividend / ShareAnnual DPS | — | $1.40 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +2.1% |
ACNB leads in 3 of 6 categories — strongest in Profitability & Efficiency and Total Returns. 1 category is tied.
MPLT vs ACNB: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is MPLT or ACNB a better buy right now?
ACNB Corporation (ACNB) offers the better valuation at 14.
6x trailing P/E (9. 8x forward), making it the more compelling value choice. Analysts rate ACNB Corporation (ACNB) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — MPLT or ACNB?
Over the past 5 years, ACNB Corporation (ACNB) delivered a total return of +105.
4%, compared to +62. 6% for MapLight Therapeutics, Inc. (MPLT). Over 10 years, the gap is even starker: ACNB returned +179. 5% versus MPLT's +62. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — MPLT or ACNB?
On balance sheet safety, MapLight Therapeutics, Inc.
(MPLT) carries a lower debt/equity ratio of 6% versus 78% for ACNB Corporation — giving it more financial flexibility in a downturn.
04Which is growing faster — MPLT or ACNB?
On earnings-per-share growth, the picture is similar: ACNB Corporation grew EPS -3.
5% year-over-year, compared to -39. 6% for MapLight Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — MPLT or ACNB?
ACNB Corporation (ACNB) is the more profitable company, earning 21.
7% net margin versus 0. 0% for MapLight Therapeutics, Inc. — meaning it keeps 21. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACNB leads at 27. 3% versus 0. 0% for MPLT. At the gross margin level — before operating expenses — ACNB leads at 73. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is MPLT or ACNB more undervalued right now?
Analyst consensus price targets imply the most upside for MPLT: 15.
4% to $33. 80.
07Which pays a better dividend — MPLT or ACNB?
In this comparison, ACNB (2.
7% yield) pays a dividend. MPLT does not pay a meaningful dividend and should not be held primarily for income.
08Is MPLT or ACNB better for a retirement portfolio?
For long-horizon retirement investors, ACNB Corporation (ACNB) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
68), 2. 7% yield, +179. 5% 10Y return). Both have compounded well over 10 years (ACNB: +179. 5%, MPLT: +62. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between MPLT and ACNB?
These companies operate in different sectors (MPLT (Healthcare) and ACNB (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: MPLT is a small-cap quality compounder stock; ACNB is a small-cap high-growth stock. ACNB pays a dividend while MPLT does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.